The effectiveness of 1% cysteamine, 3% tranexamic acid, 2% galactomyces ferment filtrate and 4% niacinamide application using double layering technique as a brightening agent: Chromameter and Janus-III analysis
DOI:
https://doi.org/10.66344/jpad.34.1.2024.2405Keywords:
Cysteamine, Double layering, Skin brightness, Topical skin lightening agentAbstract
Introduction The combination of several topical agents with different vehicles or routes of administration is one of the therapeutic strategies that can be used to increase the effectiveness and possibly to reduce unwanted side-effects.
Objective To assess the efficacy of 1% cysteamine, 3% tranexamic acid, 2% galactomyces ferment filtrate, and 4% niacinamide as a facial brightening agent using the double layering technique of serum and cream.
Methods An open-label pre-post-test clinical trial was conducted for eight weeks using on 70 type-IV Fitzpatrick skin female participants between the ages of 31-50 years-old (mean age 37.8 years). Subjects were evaluated on a biweekly basis using chromameter and Janus-III Facial Analyzer.
Results At the end of the study there was a significant L* value increase from 52.10 at W0 to 56.40 at W4 (p=0.00) along with improvement on pigmented areas from 45.52 to 43.90 after eight weeks of treatment (p=0.00 and 0.01 respectively).
Conclusion Application of 1% cysteamine, 3% tranexamic acid, 2% galactomyces ferment filtrate and 4% niacinamide using double layering technique is a promising combination for facial brightness with notable reduced side-effects.
References
1. Gu Y, Han J, Jiang C, Zhang Y. Biomarkers, oxidative stress and autophagy in skin aging. Ageing Res Rev. 2020;59:1-8.
2. Leem S, Chang J, Kim Y, et al. Repeated measurements of facial skin characteristics using the Janus-Ⅲ measurement system. Skin Res Tech. 2020;26(3):362-8. doi:10.1111/srt.12811
3. Gillbro JM, Olsson MJ. The melanogenesis and mechanisms of skin-lightening agents - Existing and new approaches. Int J Cosmet Sci. 2011;33(3):210-21.
doi:10.1111/j.1468-2494.2010.00616.x
4. Draelos ZD, Deliencourt-Godefroy G, Lopes L. An effective hydroquinone alternative for topical skin lightening. J Cosmet Dermatol. 2020;19(12):3258-61. doi:10.1111/jocd.13771
5. Anwar A, Budhiani S, Seweng A, Arimuko A, Norawati L, Veronica S. Effectiveness of application of serum and cream containing combination of tranexamic acid, galactomyces ferment filtrate, niacinamide, and alpha arbutin using layering technique in melasma. Hong Kong J Dermatol Venereol. 2020;28:5-10.
6. Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. Journal of Dermatological Treatment. 2018;29(2):182-189. doi:10.1080/09546634.2017.1351608
7. Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: A clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035-9. doi:10.1111/j.1468-3083.2012.04464.x
8. Irawan Anwar A, Wahab S, Tabri F, et al. Effectiveness of 1% cysteamine, 3% tranexamic Acid, 4% niacinamide, and 2% galactomyces ferment filtrate serum in epidermal melasma. Azerbaijan Med J. 2022;62(6):2489-94.
9. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B Vitamin that Improves Aging Facial Skin Appearance. Dermatol Surg. 2005;31(7):860-4.
10. Bissett DL, Miyamoto K, Sun P, Li J, Berge CA. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin 1. Int J Cosmet Sci. 2004;26:231-8.
11. Otte N, Borelli C, Korting HC. Nicotinamide-biologic actions of an emerging cosmetic ingredient. Int J Cosmet Sci. 2005;27:255-61.
12. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20-31.
13. Clarys P, Alewaeters K, Lambrecht R, Barel AO. Skin color measurements: Comparison between three instruments: The Chromameter®, the DermaSpectrometer® and the Mexameter®. Skin Res Tech. 2000;6(4):230-8.
doi:10.1034/j.1600-0846.2000.006004230.x
14. D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME, et al. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17(7):1144.
15. Leem S, Kim SJ, Kim Y, et al. Comparative analysis of skin characteristics evaluation by a dermatologist and the Janus-III measurement system. Skin Res Tech. 2021;27(1):86-92.
16. Karrabi M, David J, Sahebkar M. Clinical evaluation of efficacy, safety and tolerability of cysteamine 5% cream in comparison with modified Kligman’s formula in subjects with epidermal melasma: A randomized, double‐blind clinical trial study. Skin Res Tech. 2021;27(1):24-31.
17. Nguyen J, Remyn L, Chung IY, et al. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial. Australas J Dermatol. 2021;62(1):41-46.
18. Zhang T, Xu H, Zhang Y, et al. Fabrication and characterization of double-layer asymmetric dressing through electrostatic spinning and 3D printing for skin wound repair. Mater Des. 2022;218:110711.
19. Lima PB, Dias JAF, Cassiano D, et al. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women. Int J Dermatol. 2020;59(12):1531-6.
Published
Issue
Section
License
Copyright (c) 2024 Anis Anwar, Siswanto Wahab, Asvina Anis Anwar, Natalia Widjaja, Tania Azhari, Thomas Utomo, Wong Lip Wih, Jonathan Kurnia Wijaya
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
